News & Updates

Show Multimedia Only

Perioperative EV plus pembro tied to better outcomes in patients with MIBC

13 Apr 2026 by

Perioperative treatment with enfortumab vedotin and pembrolizumab (EV plus pembro) significantly improves event-free survival (EFS), overall survival (OS), and pathological complete response (pCR) rates in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy, according to the KEYNOTE-905 trial presented at EAU26.

Perioperative EV plus pembro tied to better outcomes in patients with MIBC

13 Apr 2026

Inhaled mebufotenin shows promise in treatment-resistant depression

12 Apr 2026

Single-day treatment with GH001, a synthetic formulation of inhaled mebufotenin, has been shown to be well tolerated and yield substantial improvements in depressive symptoms in patients with treatment-resistant depression in a phase IIb trial.

Inhaled mebufotenin shows promise in treatment-resistant depression

12 Apr 2026

Vaginal platelet-rich plasma injection boosts sexual function in premenopausal women

12 Apr 2026

Administering platelet-rich plasma injections to the anterior vaginal wall helps improve sexual function in sexually active premenopausal women without severe sexual dysfunction, according to a pilot, single-centre study.

Vaginal platelet-rich plasma injection boosts sexual function in premenopausal women

12 Apr 2026

Genes affect response to COVID-19 vax, standard vaccination approach appropriate for SAD patients

11 Apr 2026 by

Genetic markers, both in and outside the immune system, influence an individual’s response to the SARS-CoV-2 vaccine, and these effects are similar in patients with or without systemic autoimmune diseases (SADs), reports a study.

Genes affect response to COVID-19 vax, standard vaccination approach appropriate for SAD patients

11 Apr 2026

Semaglutide confers ASCVD risk factor benefits in high-risk patients

11 Apr 2026

Treatment with semaglutide yields early and sustained improvements in multiple atherosclerotic cardiovascular disease (ASCVD) factors in high-risk patients with type 2 diabetes (T2D) and ASCVD and/or chronic kidney disease (CKD), according to a post hoc analysis of the SOUL trial.

Semaglutide confers ASCVD risk factor benefits in high-risk patients

11 Apr 2026

Anthocyanin may reverse IGT by improving insulin sensitivity

10 Apr 2026

Supplementation with anthocyanin improves insulin sensitivity, which could then significantly reverse impaired glucose tolerance (IGT), reports a study.

Anthocyanin may reverse IGT by improving insulin sensitivity

10 Apr 2026

No link between methylphenidate use and psychosis risk among children with ADHD

10 Apr 2026

The use of methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder (ADHD) does not contribute to an increased risk of nonaffective psychosis and may even confer protection against the risk, according to a study.

No link between methylphenidate use and psychosis risk among children with ADHD

10 Apr 2026

Varenicline shows promise in vaping cessation

09 Apr 2026 by

People who wish to quit vaping may find success with the help of varenicline, which has been found in a recent study to result in numerically higher abstinence rates relative to placebo.

Varenicline shows promise in vaping cessation

09 Apr 2026

Clopidogrel vs aspirin maintenance post-PCI with DES: Which reigns better?

09 Apr 2026 by

Results from the 10-year follow-up of the HOST-EXAM* trial favour clopidogrel over aspirin as chronic maintenance therapy after percutaneous coronary intervention (PCI) with a drug-eluting stent (DES).

Clopidogrel vs aspirin maintenance post-PCI with DES: Which reigns better?

09 Apr 2026

Finerenone protects kidneys in patients with T1D + CKD

09 Apr 2026 by

Finerenone significantly reduces albuminuria vs placebo and maintains a manageable safety profile in patients with type 1 diabetes (T1D) and chronic kidney disease (CKD) receiving background therapy with renin-angiotensin-aldosterone system inhibitors (RAASi), the phase III FINE-ONE trial has shown. These findings represent an important step forward since RAASi were introduced for renoprotection in T1D more than 30 years ago.

Finerenone protects kidneys in patients with T1D + CKD

09 Apr 2026

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Perioperative EV plus pembro tied to better outcomes in patients with MIBC

Perioperative EV plus pembro tied to better outcomes in patients with MIBC

Inhaled mebufotenin shows promise in treatment-resistant depression

Inhaled mebufotenin shows promise in treatment-resistant depression

Vaginal platelet-rich plasma injection boosts sexual function in premenopausal women

Vaginal platelet-rich plasma injection boosts sexual function in premenopausal women

Genes affect response to COVID-19 vax, standard vaccination approach appropriate for SAD patients

Genes affect response to COVID-19 vax, standard vaccination approach appropriate for SAD patients

Semaglutide confers ASCVD risk factor benefits in high-risk patients

Semaglutide confers ASCVD risk factor benefits in high-risk patients

Anthocyanin may reverse IGT by improving insulin sensitivity

Anthocyanin may reverse IGT by improving insulin sensitivity

No link between methylphenidate use and psychosis risk among children with ADHD

No link between methylphenidate use and psychosis risk among children with ADHD

Varenicline shows promise in vaping cessation

Varenicline shows promise in vaping cessation

Clopidogrel vs aspirin maintenance post-PCI with DES: Which reigns better?

Clopidogrel vs aspirin maintenance post-PCI with DES: Which reigns better?

Finerenone protects kidneys in patients with T1D + CKD

Finerenone protects kidneys in patients with T1D + CKD